» Articles » PMID: 32905775

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Overview
Journal Cell Rep
Publisher Cell Press
Date 2020 Sep 9
PMID 32905775
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoprotegerin (OPG) inhibits the ability of receptor activator of nuclear factor κB (NF-κB) ligand (RANKL) to stimulate the differentiation, activity, and survival of bone-resorbing osteoclasts. Genetic studies in mice show that osteocytes are an important source of RANKL, but the cellular sources of OPG are unclear. We use conditional deletion of Tnfrsf11b, which encodes OPG, from different cell populations to identify functionally relevant sources of OPG in mice. Deletion from B lymphocytes and osteocytes, two cell types commonly thought to supply OPG, has little or no impact on bone mass. By contrast, deletion of Tnfrsf11b from osteoblasts increases bone resorption and reduces bone mass to an extent similar to germline deletion, demonstrating that osteoblasts are an essential source of OPG. These results suggest that, in addition to producing new bone matrix, osteoblasts also play an active role in terminating the resorption phase of the bone remodeling cycle by suppressing RANKL activity.

Citing Articles

The Role of Osteoprotegerin in Breast Cancer: Genetic Variations, Tumorigenic Pathways, and Therapeutic Potential.

Radhi J, El-Hagrasy A, Almosawi S, Alhashel A, Butler A Cancers (Basel). 2025; 17(3).

PMID: 39941709 PMC: 11815763. DOI: 10.3390/cancers17030337.


Hyperbaric oxygen potentiates platelet-rich plasma composition and accelerates bone healing.

Chang W, Huang C, Chen T, Chao S, Lin C, Chang C J Orthop Translat. 2025; 51:1-12.

PMID: 39902098 PMC: 11787568. DOI: 10.1016/j.jot.2024.10.016.


Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.

El-Masri B, Andreasen C, Laursen K, Kofod V, Dahl X, Nielsen M Bone Res. 2024; 12(1):62.

PMID: 39424806 PMC: 11489716. DOI: 10.1038/s41413-024-00362-4.


Metabolic reprogramming in skeletal cell differentiation.

Bertels J, He G, Long F Bone Res. 2024; 12(1):57.

PMID: 39394187 PMC: 11470040. DOI: 10.1038/s41413-024-00374-0.


The balance between helper T 17 and regulatory T cells in osteoimmunology and relevant research progress on bone tissue engineering.

Zhu S, Zhou J, Xie Z Immun Inflamm Dis. 2024; 12(9):e70011.

PMID: 39264247 PMC: 11391570. DOI: 10.1002/iid3.70011.


References
1.
Kanzaki H, Chiba M, Shimizu Y, Mitani H . Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res. 2001; 80(3):887-91. DOI: 10.1177/00220345010800030801. View

2.
Piemontese M, Xiong J, Fujiwara Y, Thostenson J, OBrien C . Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am J Physiol Endocrinol Metab. 2016; 311(3):E587-93. PMC: 5142003. DOI: 10.1152/ajpendo.00219.2016. View

3.
Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T . Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998; 247(3):610-5. DOI: 10.1006/bbrc.1998.8697. View

4.
Corral D, Amling M, Priemel M, Loyer E, Fuchs S, Ducy P . Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci U S A. 1998; 95(23):13835-40. PMC: 24916. DOI: 10.1073/pnas.95.23.13835. View

5.
Sarink D, Yang J, Johnson T, Chang-Claude J, Overvad K, Olsen A . Reproductive and Lifestyle Factors and Circulating sRANKL and OPG Concentrations in Women: Results from the EPIC Cohort. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1746-1754. DOI: 10.1158/1055-9965.EPI-19-0241. View